February 2014 Life Science Industry Research Reports

Abilify (Schizophrenia) – Forecast and Market Analysis to 2022

Published in Feb 2014 ; US $ 3495 Onwards; Publisher: GlobalData

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning […]

PharmaPoint: Schizophrenia – Current and Future Players

Published in Feb 2014 ; US $ 2995 Onwards; Publisher: GlobalData

GlobalData has released its pharma report, “PharmaPoint: Schizophrenia Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key […]

Indolent Lymphoma Global Clinical Trials Review, H1, 2014

Published in Feb 2014 ; US $ 2500 Onwards; Publisher: GlobalData

GlobalData’s clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, H1, 2014” provides data on the Indolent Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Indolent Lymphoma. It includes an overview […]

Leiomyosarcoma Global Clinical Trials Review, H1, 2014

Published in Feb 2014 ; US $ 2500 Onwards; Publisher: GlobalData

GlobalData’s clinical trial report, “Leiomyosarcoma Global Clinical Trials Review, H1, 2014” provides data on the Leiomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Leiomyosarcoma. It includes an overview of the trial […]